Saccharomyces cerevisiae CBC 1234

Saccharomyces cerevisiae CBC 1234 is a proprietary yeast strain in the Saccharomyces cerevisiae species, which produces beta-glucans and mannan-oligosaccharides that interact with intestinal immune receptors. As a probiotic yeast, it works by modulating gut-associated lymphoid tissue and competing with pathogenic organisms for intestinal adhesion sites.

Origin & History

Saccharomyces cerevisiae CBC 1234 is a proprietary variant of S. cerevisiae, a eukaryotic yeast naturally found in soil, plants, and fermented foods like bread, beer, and wine. It is propagated via fermentation and lyophilized into powder form containing live viable cells, typically standardized to ≥2.5 × 10^9 CFU per dose.

Historical & Cultural Context

No historical traditional medicine use documented for S. cerevisiae CBC 1234 in Ayurveda, TCM, or other systems. Modern probiotic application stems from its origins in food and brewery fermentation, with related S. boulardii strains used clinically since the 1950s.

Health Benefits

• No specific clinical benefits documented for CBC 1234 strain - evidence limited to general S. cerevisiae strains
• Related S. boulardii strains show reduction in acute infectious diarrhea duration by ~1 day (moderate evidence from RCTs)
• Prevention of antibiotic-associated diarrhea when taken prophylactically (moderate evidence from comparable strains)
• Adjunct therapy for C. difficile colitis alongside vancomycin/metronidazole (preliminary evidence)
• In vitro studies demonstrate epithelial barrier enhancement via increased transepithelial electrical resistance (preliminary evidence)

How It Works

Saccharomyces cerevisiae strains produce cell-wall beta-1,3/1,6-glucans and mannan-oligosaccharides that bind Dectin-1 and TLR2 receptors on intestinal dendritic cells and macrophages, triggering innate immune signaling via NF-kB and MAPK pathways. These interactions stimulate secretory IgA production and promote regulatory T-cell activity, reinforcing mucosal barrier integrity. The yeast also secretes proteases that degrade virulence factors from pathogens such as Clostridioides difficile toxins A and B, reducing their epithelial adhesion capacity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically reference Saccharomyces cerevisiae CBC 1234. Evidence is limited to general S. cerevisiae strains or S. boulardii comparators (PMID: 18416847 for strain comparison), with related strains showing efficacy in diarrhea management but no specific data for this proprietary variant.

Clinical Summary

No strain-specific randomized controlled trials have been published for Saccharomyces cerevisiae CBC 1234 as of this writing, making direct efficacy claims unsupported by clinical evidence. Extrapolation from closely related S. boulardii (CNCM I-745) RCTs — including a 2010 Cochrane review of 21 trials with over 4,500 participants — shows reduction of acute infectious diarrhea duration by approximately one day. A separate meta-analysis of 11 RCTs found S. boulardii reduced antibiotic-associated diarrhea risk by roughly 53% (RR 0.47, 95% CI 0.35–0.63). Until CBC 1234-specific trials are conducted, these outcomes cannot be confidently attributed to this strain, as probiotic effects are highly strain-dependent.

Nutritional Profile

Saccharomyces cerevisiae CBC 1234, as a yeast-based probiotic ingredient, carries the general compositional profile of S. cerevisiae cells, though exact strain-specific concentrations for CBC 1234 are not independently documented in public literature. Based on established S. cerevisiae compositional data: Protein: 40–50% of dry cell weight, comprising all essential amino acids with notably high glutamic acid, aspartic acid, and leucine content; bioavailability is moderate as intact cell walls (beta-glucan/mannan matrix) limit direct protein absorption unless cell walls are disrupted. Carbohydrates: 30–40% dry weight, primarily as beta-1,3/1,6-glucans (comprising ~30–60% of cell wall mass) and mannan-oligosaccharides (MOS); these are not absorbed but act as prebiotic-like substrates and immunomodulatory compounds. Fat: 2–6% dry weight, predominantly unsaturated fatty acids (oleic acid C18:1, palmitoleic acid C16:1). B-Vitamins: naturally rich in B-complex — thiamine (B1) ~1–5 mg/100g dry weight, riboflavin (B2) ~3–5 mg/100g, niacin (B3) ~30–50 mg/100g, pantothenic acid (B5) ~10–20 mg/100g, pyridoxine (B6) ~3–5 mg/100g, folate (B9) ~1–3 mg/100g; B12 is absent unless fortified. Minerals: chromium (as biologically active glucose tolerance factor, GTF-chromium, ~200–400 mcg/100g), selenium (strain/growth medium dependent, typically 0.1–0.3 mg/100g in standard strains), zinc (~3–8 mg/100g), iron (~2–5 mg/100g), phosphorus (~1–2 g/100g), potassium (~1.5–2 g/100g), magnesium (~200–400 mg/100g). Bioactive compounds: beta-glucans serve as key immunomodulatory agents (TLR2/Dectin-1 agonists); MOS may competitively inhibit pathogen adhesion to intestinal epithelium. Trehalose (stress-protective disaccharide) present at ~15–20% dry weight in some preparations. Ergosterol (vitamin D2 precursor) present at ~0.3–1% dry weight; conversion to vitamin D2 requires UV exposure, which is processing-dependent. Bioavailability note: As a whole-cell probiotic preparation, most intracellular nutrients have limited bioavailability unless the product undergoes autolysis or cell wall disruption processing; CBC 1234-specific processing method not publicly documented, which materially affects nutrient release and absorption.

Preparation & Dosage

No dosages studied for CBC 1234 specifically. Comparable S. cerevisiae/boulardii strains use: 250 mg (≥2.5 × 10^9 CFU) 1-3x daily for acute diarrhea; 50-200 mg 3x daily for prophylaxis; 100 mg 3x daily for 14 days then 50 mg for acne. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus acidophilus, Bifidobacterium longum, Prebiotic fibers, Zinc, Vitamin D3

Safety & Interactions

Saccharomyces cerevisiae strains are generally recognized as safe (GRAS) by the FDA and are well tolerated in healthy adults, with the most commonly reported side effects being mild bloating and flatulence during the initial days of supplementation. Individuals with immunocompromising conditions — including HIV/AIDS, organ transplant recipients, or those on systemic corticosteroids — face a rare but documented risk of fungemia (yeast infection in the bloodstream) and should avoid live yeast supplements without physician oversight. Saccharomyces supplements may interact with antifungal medications such as fluconazole, itraconazole, and amphotericin B, which can reduce or eliminate probiotic viability. Safety data in pregnancy and lactation for CBC 1234 specifically is absent; pregnant individuals should consult a healthcare provider before use.